Contact
searchSearch
HMP Global
Login

News

News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
Michele Reni, MD
Conference Coverage
Neoadjuvant PAXG Significantly Improves Survival Compared to mFOLFIRNOX in Patients With Pancreatic Ductal Adenocarcinoma
07/24/2025
Michele Reni
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses...
07/24/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Vincent Picozzi, MD
Conference Coverage
TTFields Provide Overall Survival Benefit in Locally Advanced Pancreatic Adenocarcinoma
05/31/2025
Vincent Picozzi, MD
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses results from the PANOVA-3 trial which showed the use of TTFields with gemcitabine and nab-paclitaxel significantly improved overall survival among newly diagnosed patients with locally advanced unresectable...
Vincent Picozzi, MD, discusses...
05/31/2025
Oncology
News
FOLFIRINOX Significantly Improves Progression-Free Survival for Patients With Locally Advanced Pancreatic Cancer
05/23/2025
Stephanie Holland
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN trial demonstrated that FOLFIRINOX significantly improved progression-free survival compared to gemcitabine among patients with locally advanced pancreatic cancer.
Results from the phase 3 NEOPAN...
05/23/2025
Oncology
News
Ablative Radiation Therapy Demonstrates Promise Among Patients With Resectable Pancreatic Ductal Adenocarcinoma
04/25/2025
Stephanie Holland
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a cohort study, ablative radiation therapy demonstrated clinical promise among patients with technically resectable pancreatic ductal adenocarcinoma.
According to results from a...
04/25/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use